| Medical and Health Sciences | Lifetime | 737 | US 379 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 645 | US 220 | 99.86 |
| Biological Sciences | 2021-2025 | 970 | US 226 | 98.93 |
| Molecular Biology | Lifetime | 193 | US 136 | 99.91 |
| Hematology | Lifetime | 23 | US 18 | 99.86 |
| Clinical Neurology | Lifetime | 166 | US 73 | 99.39 |
| Medical Genetics | Lifetime | 168 | US 87 | 98.78 |
| Oncology | Lifetime | 601 | US 328 | 98.84 |
| Pathology and Forensic Medicine | Lifetime | 957 | US 432 | 95.10 |
| Nephrology | Lifetime | 620 | US 294 | 92.56 |
| Molecular Biology | 2021-2025 | 195 | US 54 | 99.21 |
| Hematology | 2021-2025 | 66 | US 36 | 98.56 |
| Oncology | 2021-2025 | 640 | US 285 | 90.44 |
| Clinical Neurology | 2021-2025 | 331 | US 134 | 89.96 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 2 | US 2 | 99.93 |
| Multiple Myeloma Research and Treatments | Lifetime | 11 | US 8 | 99.93 |
| Peptidase Inhibition and Analysis | Lifetime | 25 | US 14 | 99.84 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 15 | US 9 | 99.76 |
| Parathyroid Disorders and Treatments | Lifetime | 18 | US 11 | 99.63 |
| Protein Degradation and Inhibitors | Lifetime | 16 | US 11 | 99.81 |
| Peripheral Neuropathies and Disorders | Lifetime | 15 | US 4 | 99.84 |
| Neuroendocrine Tumor Research Advances | Lifetime | 48 | US 26 | 99.67 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 65 | US 41 | 99.73 |
| Autoimmune Bullous Skin Diseases | Lifetime | 30 | US 14 | 99.50 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 11 | US 4 | 99.51 |
| Cancer Treatment and Pharmacology | Lifetime | 82 | US 47 | 99.71 |
| Dermatological and Skeletal Disorders | Lifetime | 22 | US 12 | 99.16 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 19 | US 8 | 98.86 |
| Eosinophilic Disorders and Syndromes | Lifetime | 84 | US 47 | 99.15 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 133 | US 56 | 98.53 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 304 | US 156 | 98.54 |
| Drug Transport and Resistance Mechanisms | Lifetime | 463 | US 183 | 97.99 |
| Hereditary Neurological Disorders | Lifetime | 108 | US 38 | 97.75 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 388 | US 171 | 97.92 |
| Viral-associated cancers and disorders | Lifetime | 445 | US 208 | 97.60 |
| Lymphoma Diagnosis and Treatment | Lifetime | 968 | US 417 | 97.83 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 190 | US 79 | 97.14 |
| Pancreatitis Pathology and Treatment | Lifetime | 812 | US 304 | 96.90 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 649 | US 330 | 95.98 |
| Platelet Disorders and Treatments | Lifetime | 985 | US 381 | 95.66 |
| Autoimmune Neurological Disorders and Treatments | Lifetime | 258 | US 64 | 93.65 |
| Hematological disorders and diagnostics | Lifetime | 699 | US 312 | 92.09 |
| Chemokine receptors and signaling | Lifetime | 811 | US 307 | 90.94 |
| Histiocytic Disorders and Treatments | Lifetime | 705 | US 319 | 85.80 |
| Hypertrophic osteoarthropathy and related conditions | Lifetime | 202 | US 58 | 65.00 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 6 | US 3 | 99.56 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 54 | US 22 | 99.26 |
| Parathyroid Disorders and Treatments | 2021-2025 | 39 | US 12 | 97.91 |
| Dermatological and Skeletal Disorders | 2021-2025 | 10 | US 6 | 94.59 |
| Protein Degradation and Inhibitors | 2021-2025 | 179 | US 87 | 95.97 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 167 | US 95 | 95.93 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 48 | US 11 | 93.49 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 112 | US 40 | 94.13 |
| Cancer Treatment and Pharmacology | 2021-2025 | 340 | US 121 | 93.21 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 197 | US 96 | 91.44 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 561 | US 130 | 90.64 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 530 | US 234 | 90.59 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 341 | US 61 | 91.24 |
| Peptidase Inhibition and Analysis | 2021-2025 | 761 | US 182 | 88.01 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 775 | US 199 | 87.63 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 677 | US 124 | 81.72 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 140 | US 23 | 79.60 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 791 | US 188 | 79.49 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 660 | US 157 | 78.11 |
| Viral-associated cancers and disorders | 2021-2025 | 814 | US 292 | 79.97 |
| Medical Imaging and Pathology Studies | 2021-2025 | 849 | US 253 | 74.74 |
| Hematological disorders and diagnostics | 2021-2025 | 709 | US 174 | 55.78 |
